Interethnic variability of ERCC2 polymorphisms

C. R. King, J. Yu, Robert Freimuth, H. L. McLeod, S. Marsh

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2) plays an important role in DNA repair by eliminating bulky DNA adducts produced by platinum agents during the nucleotide excision repair pathway. Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity. This study examined ERCC2 polymorphisms and haplotype structure across 18.9 kb in 95 European, 95 African, and 95 Asian individuals. Single-nucleotide polymorphisms (SNPs) (ERCC2 -9164 A>T, -1989 A>G, -516 G>A, 468 C>A [Arg156Arg], 1737 C>T [Val579Val], 2133 C>T [Asp711Asp], and 2251 T>G [Lys751Gln]) were mined and mapped using Golden Path, PolyMAPr, and Promolign. Genotyping was performed using PCR and pyrosequencing. Allele frequencies ranged from 0 to 0.47 (Europeans), 0.05 to 0.72 (Africans), and 0 to 0.47 (Asians). The synonymous cSNP at codon 579 could not be confirmed in our populations. There were significant differences in haplotype structure and frequency between populations. This information on ERCC2 genomic structure will allow the construction of definitive studies to clarify the clinical role of this important gene.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalPharmacogenomics Journal
Volume5
Issue number1
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

DNA Repair
Rodentia
Platinum
Haplotypes
DNA Adducts
Gene Frequency
Codon
Population
Single Nucleotide Polymorphism
Lung Neoplasms
Polymerase Chain Reaction
Genes

Keywords

  • ERCC2
  • Pharmacogenetics
  • Polymorphism

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Interethnic variability of ERCC2 polymorphisms. / King, C. R.; Yu, J.; Freimuth, Robert; McLeod, H. L.; Marsh, S.

In: Pharmacogenomics Journal, Vol. 5, No. 1, 2005, p. 54-59.

Research output: Contribution to journalArticle

King, C. R. ; Yu, J. ; Freimuth, Robert ; McLeod, H. L. ; Marsh, S. / Interethnic variability of ERCC2 polymorphisms. In: Pharmacogenomics Journal. 2005 ; Vol. 5, No. 1. pp. 54-59.
@article{f9443fb17aba43838f7437d131690869,
title = "Interethnic variability of ERCC2 polymorphisms",
abstract = "Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2) plays an important role in DNA repair by eliminating bulky DNA adducts produced by platinum agents during the nucleotide excision repair pathway. Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity. This study examined ERCC2 polymorphisms and haplotype structure across 18.9 kb in 95 European, 95 African, and 95 Asian individuals. Single-nucleotide polymorphisms (SNPs) (ERCC2 -9164 A>T, -1989 A>G, -516 G>A, 468 C>A [Arg156Arg], 1737 C>T [Val579Val], 2133 C>T [Asp711Asp], and 2251 T>G [Lys751Gln]) were mined and mapped using Golden Path, PolyMAPr, and Promolign. Genotyping was performed using PCR and pyrosequencing. Allele frequencies ranged from 0 to 0.47 (Europeans), 0.05 to 0.72 (Africans), and 0 to 0.47 (Asians). The synonymous cSNP at codon 579 could not be confirmed in our populations. There were significant differences in haplotype structure and frequency between populations. This information on ERCC2 genomic structure will allow the construction of definitive studies to clarify the clinical role of this important gene.",
keywords = "ERCC2, Pharmacogenetics, Polymorphism",
author = "King, {C. R.} and J. Yu and Robert Freimuth and McLeod, {H. L.} and S. Marsh",
year = "2005",
doi = "10.1038/sj.tpj.6500283",
language = "English (US)",
volume = "5",
pages = "54--59",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Interethnic variability of ERCC2 polymorphisms

AU - King, C. R.

AU - Yu, J.

AU - Freimuth, Robert

AU - McLeod, H. L.

AU - Marsh, S.

PY - 2005

Y1 - 2005

N2 - Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2) plays an important role in DNA repair by eliminating bulky DNA adducts produced by platinum agents during the nucleotide excision repair pathway. Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity. This study examined ERCC2 polymorphisms and haplotype structure across 18.9 kb in 95 European, 95 African, and 95 Asian individuals. Single-nucleotide polymorphisms (SNPs) (ERCC2 -9164 A>T, -1989 A>G, -516 G>A, 468 C>A [Arg156Arg], 1737 C>T [Val579Val], 2133 C>T [Asp711Asp], and 2251 T>G [Lys751Gln]) were mined and mapped using Golden Path, PolyMAPr, and Promolign. Genotyping was performed using PCR and pyrosequencing. Allele frequencies ranged from 0 to 0.47 (Europeans), 0.05 to 0.72 (Africans), and 0 to 0.47 (Asians). The synonymous cSNP at codon 579 could not be confirmed in our populations. There were significant differences in haplotype structure and frequency between populations. This information on ERCC2 genomic structure will allow the construction of definitive studies to clarify the clinical role of this important gene.

AB - Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2) plays an important role in DNA repair by eliminating bulky DNA adducts produced by platinum agents during the nucleotide excision repair pathway. Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity. This study examined ERCC2 polymorphisms and haplotype structure across 18.9 kb in 95 European, 95 African, and 95 Asian individuals. Single-nucleotide polymorphisms (SNPs) (ERCC2 -9164 A>T, -1989 A>G, -516 G>A, 468 C>A [Arg156Arg], 1737 C>T [Val579Val], 2133 C>T [Asp711Asp], and 2251 T>G [Lys751Gln]) were mined and mapped using Golden Path, PolyMAPr, and Promolign. Genotyping was performed using PCR and pyrosequencing. Allele frequencies ranged from 0 to 0.47 (Europeans), 0.05 to 0.72 (Africans), and 0 to 0.47 (Asians). The synonymous cSNP at codon 579 could not be confirmed in our populations. There were significant differences in haplotype structure and frequency between populations. This information on ERCC2 genomic structure will allow the construction of definitive studies to clarify the clinical role of this important gene.

KW - ERCC2

KW - Pharmacogenetics

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=13544255725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544255725&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500283

DO - 10.1038/sj.tpj.6500283

M3 - Article

C2 - 15534626

AN - SCOPUS:13544255725

VL - 5

SP - 54

EP - 59

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 1

ER -